Acthrel Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

This Acthrel market report delivers an in-depth analysis of the market’s key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.

Market growth during the historic period can be attributed to the rising prevalence of hormone-related disorders, increased focus on diagnostic tools for endocrine conditions, growing awareness of pituitary and adrenal gland dysfunctions, enhanced healthcare infrastructure, and the growing incidence of stress-related health issues affecting hormone levels.

The projected growth in the forecast period is driven by the increasing demand for early diagnosis of hormonal imbalances, a higher number of medical procedures involving ACTH testing, rising healthcare spending, and the growth of specialized endocrine diagnostic centers. Key trends during this period include the increased use of non-invasive diagnostic technologies, the development of combination diagnostic kits, the integration of artificial intelligence in diagnostic testing, a rise in patient-centric healthcare solutions, and the adoption of point-of-care testing options.

The increasing demand for diagnostic testing is anticipated to drive the growth of the acthrel market in the coming years. Diagnostic testing refers to the medical procedures used to confirm or identify diseases and conditions in patients. The rising demand for diagnostic testing is attributed to advancements in medical technology, a greater focus on early disease detection, heightened health awareness, and an aging population. Acthrel plays a critical role in diagnostic testing by stimulating the pituitary gland to release adrenocorticotropic hormone (ACTH), which is essential for evaluating adrenal gland function and diagnosing conditions such as adrenal insufficiency and disorders of the hypothalamic-pituitary-adrenal (HPA) axis. For example, the UK government’s Department of Health and Social Care announced plans to establish up to 160 community diagnostic centers across England by 2025, with 73 already operational as of April 2022. This initiative is backed by increased funding, which contributes to the growing demand for diagnostic testing and, in turn, the acthrel market.

Rising healthcare expenditure is another key factor fueling the acthrel market. Healthcare expenditure refers to the financial resources allocated to healthcare services and goods, which is increasing due to factors such as a higher number of patients requiring treatment, expensive medical technologies, an aging population, and rising drug prices. Acthrel contributes to the increase in healthcare spending by enabling accurate testing of the HPA axis, which is crucial for diagnosing complex endocrine disorders such as adrenal insufficiency and Cushing's syndrome. For instance, the Centers for Medicare & Medicaid Services projected an annual average increase in national health spending of 5.1% from 2021 to 2030, reaching nearly $6.8 trillion by 2030, as outlined in the 2021-2030 National Health Expenditure report. This increase in healthcare expenditure supports growth in diagnostic tools, therapeutic interventions, and specialized healthcare services, driving demand for acthrel.

The growing incidence of endocrine diseases is also contributing to the expansion of the acthrel market. Endocrine diseases, which affect hormone-producing glands, result in imbalances that impact various body functions. The rising prevalence of conditions such as diabetes, thyroid disorders, and adrenal insufficiency is driven by factors such as obesity, stress, genetic predisposition, environmental exposures, and an aging population. Acthrel aids in diagnosing and managing adrenal and other endocrine disorders, supporting the growing need for accurate diagnostic evaluations of the HPA axis. For example, in March 2024, the Office for Health Improvement and Disparities reported a 22% increase in the percentage of individuals with type 1 diabetes receiving all recommended care processes, reflecting growing awareness and care for endocrine diseases. This increase in the incidence of endocrine disorders is expected to further drive the demand for acthrel.

The key company operating in the acthrel market is Ferring Pharmaceuticals.

North America was the largest region in the acthrel market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in acthrel report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the acthrel market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Acthrel (corticorelin ovine triflutate) is a synthetic version of corticotropin-releasing hormone (CRH) used for diagnostic testing of the hypothalamic-pituitary-adrenal (HPA) axis function. It helps diagnose adrenal insufficiency, differentiate causes of Cushing’s syndrome, and assess pituitary gland function in medical settings.

The primary applications of acthrel include diagnosing adrenal insufficiency, conducting HPA axis testing, and supporting medical research. Adrenal insufficiency diagnosis involves a series of tests to evaluate whether the adrenal glands are producing sufficient levels of hormones, mainly cortisol, to meet the body’s requirements. It is primarily used for adults and elderly patients. Acthrel is distributed through hospitals, clinics, retail pharmacies, and specialty pharmacies, ensuring availability across various healthcare settings.

The acthrel market research report is one of a series of new reports that provides acthrel market statistics, including acthrel industry global market size, regional shares, competitors with an acthrel market share, detailed acthrel market segments, market trends and opportunities, and any further data you may need to thrive in the acthrel industry. This acthrel market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The acthrel market consists of sales of products such as lyophilized powder intended for injection. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.